• Wednesday, March 17, 2021 @ 12:00 am

"Santersus' highly selective plasmapheresis treatment is demonstrably effective in the removal of up to 99% of circulating NETs from animals in septic shock as measured by our Nu.Q NETs assay. The results also show that the treatment leads to a stabilization of NETs in circulation and a great improvement in the well-being of the treated animal. This is the first study reported to use Volition's simple, low-cost Nu.Q immunoassays to monitor response to a treatment," explains Dr. Jake Micallef, Volition's Chief Scientific Officer.

You may also be interested in